Qube Research & Technologies LTD Prelude Therapeutics Inc Transaction History

Qube Research & Technologies LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.32 - $5.63 $10,378 - $17,599	3,126 New	3,126 $11,000
Q1 2023 May 15, 2023	BUY	$4.58 - $7.34 $79,005 - $126,615	17,250 Added 131.41%	30,377 $173,000
Q4 2022 Feb 14, 2023	BUY	$4.61 - $8.5 $60,515 - $111,579	13,127 New	13,127 $79,000
Q1 2022 May 09, 2022	SELL	$6.9 - $13.22 $161,349 - $309,136	-23,384 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$11.89 - $31.74 $278,035 - $742,208	23,384 New	23,384 $291,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $35.6M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.